Wells and Enteric Disease Transmission

NCT ID: NCT04826991

Last Updated: 2025-05-04

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

908 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-07-01

Study Completion Date

2027-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Approximately 40 million people in the US are served by private, and frequently untreated, wells. Our best estimate is that 1.3 million cases of gastrointestinal illnesses (GI) per year are attributed to consuming water from untreated private wells in the US, but in reality, there are no robust epidemiological data that can be used to estimate cases of GI attributable to these sources. We propose the first randomized controlled trial (RCT) to estimate the burden of GI associated with private well water. We will test if household treatment of private well water by ultraviolet light (UV) vs. sham (inactive UV device) decreases the incidence of GI in children under 5. We will also examine the presence of viral, bacterial, and protozoan pathogens in stool and well water from participants. These data will fill a knowledge gap on sporadic GI associated with federally-unregulated private water supplies in the US.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Investigators will conduct a triple-blinded randomized controlled trial of a whole-home UV water treatment device in southeastern Pennsylvania. Participating families will be randomized to receive an active UV device or a sham (inactive) UV device. Following the installation of the device, participants will be followed for one year. During that year, participants will respond to weekly text messages to report the presence of symptoms associated with gastrointestinal and respiratory illness in their children. Upon reporting symptoms, participants will complete an illness questionnaire on details regarding the illness and other potential exposure events. A subset of participants will submit groundwater samples as well as stool and saliva samples from their children. Water and stool samples will be analyzed for common waterborne pathogens. Saliva samples will be analyzed for immunoconversions to common waterborne pathogens (exploratory aim).

Under the guidance of an interdisciplinary advisory committee we will execute the following aims:

Aim 1- Quantify the incidence rate of endemic childhood GI associated with consuming untreated private well water and compare that to the incidence rate of consuming well water treated by UV.

Aim 1a- Construct a Quantitative Microbial Risk Assessment (QMRA) using water quality data we collect to estimate the risk of childhood GI associated with consuming untreated private well water and compare the incidence from the risk model to the incidence we calculate in Aim 1.

Aim 2- Identify, quantify and compare viral, bacterial and protozoan pathogens in stool of children consuming UV treated or untreated (sham) private well water (including both asymptomatic and symptomatic cases).

Aim 3- Explore the presence of pathogens in untreated well water and stool samples of children consuming untreated private well water (sham group only).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diarrhea Gastrointestinal Infection Respiratory Viral Infection Waterborne Diseases

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

A whole-home UV water treatment system will be installed and operated at a minimum of 50 millijoules per square centimeter.
Primary Study Purpose

PREVENTION

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors
Participants, device installers, investigators, and outcomes assessor will all be blinded.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Active UV Device

A household water treatment device with a lamp emitting germicidal UV. The device will be operated at 50 millijoule per square centimeter to treat \>99.9% of all bacteria, protozoa, and most viruses in water supplies.

Group Type ACTIVE_COMPARATOR

Active UV Device

Intervention Type DEVICE

Active water treatment system

Inactive UV Device

A household water treatment device with a lamp not emitting germicidal UV but still emitting light (appears identical to the active UV device).

Group Type SHAM_COMPARATOR

Inactive UV Device

Intervention Type DEVICE

Inactive water treatment system

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Active UV Device

Active water treatment system

Intervention Type DEVICE

Inactive UV Device

Inactive water treatment system

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Child resides in Adams, Berks, Bucks, Carbon, Chester, Columbia, Cumberland, Dauphin, Delaware, Lackawanna, Lancaster, Lebanon, Lehigh, Luzerne, Monroe, Montgomery, Montour, Northumberland, Northampton, Perry, Pike, Schuylkill, Wayne, Wyoming, and York county in Pennsylvania and all counties in New Jersey.
* Household is served by a private well
* Participant child is under the age of 5 (under 4 at time of enrollment), who is a full-time resident of the home and drinks untreated well water
* Parent/guardian has access to a phone with texting capabilities

Exclusion Criteria

* Child participant is immunocompromised
* Child participant has a chronic gastrointestinal condition
* Child takes daily oral steroids
* Household treats water for microbiological contamination before consumption
* Child exclusively drinks bottled water
Minimum Eligible Age

6 Months

Maximum Eligible Age

59 Months

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

Sponsor Role collaborator

Temple University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Heather Murphy

Adjunct Associate Research Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Heather M Murphy, PhD

Role: PRINCIPAL_INVESTIGATOR

Temple University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Temple University

Philadelphia, Pennsylvania, United States

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Heather M Murphy, PhD

Role: CONTACT

(215)204-5124

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Heather M Murphy, PhD

Role: primary

(215)204-5124

References

Explore related publications, articles, or registry entries linked to this study.

Lee D, Denno D, Tarr P, Wu J, Stokdyk JP, Borchardt M, Murphy HM. Study design and methods of the Wells and Enteric disease Transmission (WET) Trial: a randomised controlled trial. BMJ Open. 2023 Mar 2;13(3):e068560. doi: 10.1136/bmjopen-2022-068560.

Reference Type DERIVED
PMID: 36863739 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

R01AI153376-01

Identifier Type: NIH

Identifier Source: secondary_id

View Link

25665-A (Full Trial)

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

WASH Benefits Bangladesh
NCT01590095 UNKNOWN NA